Chen et al. interpreted that sorafenib, which is a multi-kinase inhibitor with activity against VEGFR, PDGFR and RAF kinases, attenuated bleomycin-induced pulmonary fibrosis via prohibition of fibroblast proliferation and EMT33. This evidence concerns the gene KDR and pulmonary fibrosis.